DENVER, CO / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one...
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4...
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
DENVER, CO / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended...
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Webcasted presentation to take place at 4:40 p.m. Eastern timeDENVER, CO / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow,...
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 millionQ2 2024 ADHD Portfolio net revenue up 49%...
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
DENVER, CO / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period...
Aytu BioPharma (AYTU) Fireside Chat
In this discussion, we welcome Aytu BioPharma, NASDAQ ticker symbol AYTU. And with us today is their Chief Executive Officer, Josh Disbrow. This Fireside Chat was recorded during the Lytham Partners 2024 Investor Select Conference.
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
DENVER, CO / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings...
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
DENVER, CO / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings...
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Webcasted presentation to take place at 1:10pm ETDENVER, CO / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be...